Pernix Therapeutics is a specialty pharmaceutical company that was founded in 1996. Headquartered in The Woodlands, Texas, Pernix Therapeutics primarily focuses on the sales, marketing and development of branded, generic and OTC pharmaceutical products.
For more information about Pernix Therapeutics and other available products, please visit www.pernixtx.com
Omeclamox-Pak® is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. The most frequently reported adverse events with Omeclamox-Pak were diarrhea, headache, and taste perversion. No adverse events unique to triple therapy were observed. Adverse reactions were limited to those previously reported with omeprazole, clarithromycin or amoxicillin alone.
© 2012 Pernix Therapeutics All rights reserved OME12-WS-00 6/2012 This information is intended only for residents of the United States.
